Literature DB >> 35711068

A Hypoxia-Sensitive Drug Delivery System Constructed by Nitroimidazole and its Application in the Treatment of Hepatocellular Carcinoma.

Tingting Meng1, Yinghong Li2, Ying Tian3, Mingxing Ma3, Kequan Shi1, Xuwei Shang1, Hong Yuan1, Fuqiang Hu4.   

Abstract

Hypoxia is an important pathological phenomenon, and it can induce many tumor microenvironment changes, such as accumulations of intracellular lactic acid, decrease of tumor microenvironment pH value, and regulate a series of physiological and pathological processes such as adhesion, metastasis, and immune escape. Hypoxic tumor cells act as a key target for treating tumor. In this research, we designed and prepared PEG-nitroimidazole grafts, PEG-NI, and FA-PEG-NI. We first explored their physical and chemical properties to serve as a drug carrier. Then, the hypoxia-sensitive properties such as particle size changes and drug release were investigated. Finally, the tumor targeting ability was studied in vitro and in vivo, and anti-tumor capacity was determined. Both grafts showed excellent property as a nanodrug carrier and showed favorable drug encapsulation ability of sorafenib with the help of the hydrophobic chain of 6-(BOC-amino) hexyl bromide. The micelles responded to the hypoxic tumor environment with chemical and spatial structure changes leading to sensitive and fast drug release. With the modification of folic acid, FA-PEG-NI gained tumor targeting ability in vivo. FA-PEG-NI graft proved a potential targeting drug delivery system in the treatment of hypoxic hepatocellular carcinoma.
© 2022. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.

Entities:  

Keywords:  PEG-nitroimidazole grafts; folic acid; hepatocellular carcinoma; hypoxia sensitive

Mesh:

Substances:

Year:  2022        PMID: 35711068     DOI: 10.1208/s12249-022-02316-7

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  17 in total

1.  Standardizing management of hepatocellular carcinoma in China: devising evidence-based clinical practice guidelines.

Authors:  Peipei Song
Journal:  Biosci Trends       Date:  2013-10       Impact factor: 2.400

2.  Combination therapy with sorafenib and radiofrequency ablation for hepatocellular carcinoma: a glimmer of light after the storm trial?

Authors:  Antonio Facciorusso; Nicola Muscatiello; Alfredo Di Leo; Michele Barone
Journal:  Am J Gastroenterol       Date:  2015-05       Impact factor: 10.864

Review 3.  Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Trends Pharmacol Sci       Date:  2012-03-06       Impact factor: 14.819

Review 4.  Medical therapies for hepatocellular carcinoma: a critical view of the evidence.

Authors:  Augusto Villanueva; Virginia Hernandez-Gea; Josep M Llovet
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-11-13       Impact factor: 46.802

Review 5.  Hypoxic control of metastasis.

Authors:  Erinn B Rankin; Amato J Giaccia
Journal:  Science       Date:  2016-04-07       Impact factor: 47.728

Review 6.  Hypoxia-responsive nanoparticle based drug delivery systems in cancer therapy: An up-to-date review.

Authors:  Rashmi Kumari; Dhanya Sunil; Raghumani S Ningthoujam
Journal:  J Control Release       Date:  2019-12-24       Impact factor: 9.776

Review 7.  Salvage liver transplant for hepatocellular carcinoma: rescues and benefits.

Authors:  Shusen Zheng; Qinfen Xie; Jinkun Cheng
Journal:  Transl Gastroenterol Hepatol       Date:  2018-09-17

8.  Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells.

Authors:  Hai-Shan Peng; Ming-Bin Liao; Mei-Yin Zhang; Yin Xie; Li Xu; Yao-Jun Zhang; X F Steven Zheng; Hui-Yun Wang; Yi-Fei Chen
Journal:  PLoS One       Date:  2014-06-23       Impact factor: 3.240

9.  Effect of a hypoxic microenvironment after radiofrequency ablation on residual hepatocellular cell migration and invasion.

Authors:  Yuyang Tong; Haiyun Yang; Xiaolin Xu; Jingliang Ruan; Ming Liang; Jiayi Wu; Baoming Luo
Journal:  Cancer Sci       Date:  2017-04-19       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.